Adicet Bio, Inc. (ACET): Nasdaq/NYSE listing notice — Adicet Bio receives Nasdaq delisting notice for bid price below $1; cure period to Oct 6, 2025

Adicet Bio, Inc.

Received Nasdaq notice on April 7, 2025 for non-compliance with minimum bid price rule (closing bid <$1 for 30 consecutive days).
Initial compliance period ends October 6, 2025; must close at or above $1 for at least 10 consecutive days to regain compliance.
If not cured, may seek additional 180-day period by transferring to Nasdaq Capital Market and meeting other listing standards.
Company considering reverse stock split as a potential cure; no assurance of regaining compliance or maintaining listing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Adicet Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

April 7, 2025, Adicet Bio, Inc. (the “Company”) received a notice from the Listing Qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) that because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). The letter does not result in the immediate delisting of the Company’s Common Stock, and the Company’s Common Stock will conti

View on SEC.gov

Browse all listing & compliance notices →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-053238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.